Clinical Trials in Minneapolis

Showing 3621-3640 of 12,418 trials

HPV Vaccine Intervention for Young Sexual Minority Men

NCT04032106

This phase III trial studies how well the Outsmart HPV intervention works in increasing HPV vaccine initiation and completion among young individuals who report having a history of same-sex partners, being sexually attracted to males, or identify as gay, bisexual, or queer (i.e., sexual minority males). The Outsmart HPV intervention, which is a population-targeted, individually-tailored mHealth intervention that includes vaccine reminders, may increase HPV vaccine initiation and completion among unvaccinated young sexual minority individuals.

Healthy Subject

Ohio State University Comprehensive Cancer Center1,227 participantsStarted Oct 2019

Minneapolis, Minnesota, United States • Columbus, Ohio, United States

COMPLETEDPhase 2/3< 1 mile

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

NCT05648110

AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061. Sub-study: This Phase II sub-study of SUPERNOVA will assess the safety, PK, and predicted neutralizing activity of AZD3152 compared with EVUSHELD for pre-exposure prophylaxis of COVID-19.

COVID-19, SARS-CoV-2

AstraZeneca3,882 participantsStarted Dec 2022

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Mobile, Alabama, United States +212 more locations

HPV Vaccine Intervention for Young Sexual Minority Men

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

Find Trials by Condition in Minneapolis

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

A Study of LY3561774 in Participants With Mixed Dyslipidemia

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay